MYDA Advisors LLC Invests $1.28 Million in Cellebrite DI Ltd. (NASDAQ:CLBT)

MYDA Advisors LLC bought a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 58,200 shares of the company's stock, valued at approximately $1,282,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NewEdge Advisors LLC grew its holdings in shares of Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. R Squared Ltd bought a new position in Cellebrite DI in the fourth quarter valued at approximately $100,000. Polen Capital Management LLC acquired a new position in shares of Cellebrite DI during the 4th quarter worth approximately $222,000. Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI during the 4th quarter worth approximately $234,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Cellebrite DI in the 4th quarter valued at approximately $274,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

NASDAQ:CLBT traded down $0.12 during mid-day trading on Friday, reaching $19.44. 227,162 shares of the company's stock were exchanged, compared to its average volume of 1,406,612. The firm has a market capitalization of $4.66 billion, a PE ratio of -13.99, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The business's fifty day simple moving average is $18.75 and its two-hundred day simple moving average is $20.10.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

CLBT has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, Lake Street Capital raised their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI currently has an average rating of "Buy" and an average price target of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.